Hims & Hers Health stock rally continues as discounted cash flow suggests undervaluation

Traders Union
All News
Stocks
Hims & Hers Health jumps 6.03% today

Highlights

Shares of Hims & Hers Health delivered strong gains for shareholders over three years, maintaining a strong growth track record.
Discounted cash flow analysis suggests the stock remains undervalued, but regulatory risk persists due to the FTC privacy lawsuit.
The stock trades with bullish momentum above key support levels, with price expected in the $30.65 to $36.91 range over the coming days.

Sustained growth and undervaluation offset by FTC lawsuit risk

Hims & Hers Health has reported a substantial three-year gain for shareholders, underscoring a track record of strong growth performance that continues to attract market attention. Despite these gains, the stock is still viewed as undervalued based on a discounted cash flow analysis, pointing to perceived upside on fundamental grounds, according to Simplywall. At the same time, the ongoing FTC privacy lawsuit injects a degree of caution into sentiment, as regulatory uncertainty weighs on near-term positioning.

Upward bias sustained as buyers dominate and overbought signals loom

On the technical front, HIMS is trading above the MA-20 at $32.08 and the MA-50 at $29.94 on the hourly chart, and remains well above the MA-200 at $28.89 on the daily timeframe. The Ichimoku Kijun level at $30.92 is acting as immediate support. Among momentum indicators, both MACD and ADX maintain Buy signals, while RSI at 73.04 and CCI are also in Buy territory, highlighting strong upward pressure; however, RSI is close to overbought conditions and Stochastic RSI is Neutral, indicating limited upward extension or potential for some consolidation. Bull/Bear Power registers buyers in control, while the Awesome Oscillator reads Neutral, suggesting mild divergence from the prevailing directional move.

Consolidation likely as bullish momentum challenges resistance range

Looking ahead, HIMS is expected to trade within a range of $30.65 to $36.91 over the next several days. There is a very high probability of continued upward momentum, with a move lower considered unlikely in the current volatility band. The baseline scenario is for price to consolidate near or just above current levels. Should bullish momentum persist, a break above the upper end of the range is possible, while a drop below immediate support at $30.92 would signal a shift to a bearish scenario.

Viktoras Karapetjanc, expert at Traders Union, sees HIMS as a fundamentally strong story with positive momentum. He believes that the large three-year shareholder gain and undervaluation on DCF create a solid case for further upside. Although the FTC lawsuit introduces some caution, market sentiment remains constructive. Technical signals also favor the bulls, with immediate support at $30.92. "As long as regulatory risks are contained and momentum holds, I expect HIMS to consolidate or extend gains above current levels."

Earlier, analysts noted that Hims & Hers Health maintained a strong technical uptrend supported by robust earnings momentum, though mixed momentum signals and legal scrutiny warranted vigilance. The latest price action and indicator alignment reinforce the bullish outlook, with consolidation near current levels likely, but continued monitoring of the $30.92 support remains essential amid prevailing volatility and regulatory uncertainties.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.